Key facts
- PulseSight Therapeutics’s last known valuation is $64.5M (Aug 2021).
- It has raised $57.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Bpifrance, Korea Investment Partners, Kinled Holding, Boehringer Ingelheim Venture Fund, SPRIM Global Investments — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for PulseSight Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for PulseSight Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PulseSight Therapeutics
Developer of therapeutic proteins designed to treat severe retinal diseases. The company's proteins treat both short and long-term conditions like chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases and macular edema, as well as enhance compliance, ocular bioavailability and tolerability, enabling physicians and ophthalmologists to improve quality of life and preserve vision for patients.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2008
- Employees
- 13
- Website
- pulsesight.com/
- Ownership
- Privately Held (backing)
PulseSight Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PulseSight Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PulseSight Therapeutics in its N-PORT filings yet. We sweep new filings monthly.